Sign In
Buy TMSNY
Temenos AG Earnings Calls
| Release date | May 28, 2026 |
| EPS estimate | $0.84 |
| EPS actual | $0.590 |
| EPS Surprise | -29.76% |
| Revenue estimate | 245.49M |
| Revenue actual | 252.956M |
| Revenue Surprise | 3.04% |
| Release date | Feb 26, 2026 |
| EPS estimate | $1.02 |
| EPS actual | $0.620 |
| EPS Surprise | -39.22% |
| Revenue estimate | 300.8M |
| Revenue actual | 320.837M |
| Revenue Surprise | 6.66% |
| Release date | Oct 28, 2025 |
| EPS estimate | - |
| EPS actual | $0.642 |
| Revenue estimate | - |
| Revenue actual | 257.911M |
| Release date | Jul 22, 2025 |
| EPS estimate | $0.758 |
| EPS actual | $2.32 |
| EPS Surprise | 206.07% |
| Revenue estimate | 246.839M |
| Revenue actual | 285.472M |
| Revenue Surprise | 15.65% |
Last 4 Quarters for Temenos AG
Below you can see how TMSNY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 22, 2025 |
| Price on release | $78.98 |
| EPS estimate | $0.758 |
| EPS actual | $2.32 |
| EPS surprise | 206.07% |
| Date | Price |
|---|---|
| Jul 16, 2025 | $72.81 |
| Jul 17, 2025 | $73.76 |
| Jul 18, 2025 | $74.16 |
| Jul 21, 2025 | $73.81 |
| Jul 22, 2025 | $78.98 |
| Jul 23, 2025 | $92.65 |
| Jul 24, 2025 | $91.77 |
| Jul 25, 2025 | $90.29 |
| Jul 28, 2025 | $90.03 |
| 4 days before | 8.47% |
| 4 days after | 13.99% |
| On release day | 17.30% |
| Change in period | 23.65% |
| Release date | Oct 28, 2025 |
| Price on release | $84.39 |
| EPS estimate | - |
| EPS actual | $0.642 |
| Date | Price |
|---|---|
| Oct 22, 2025 | $79.83 |
| Oct 23, 2025 | $79.22 |
| Oct 24, 2025 | $79.69 |
| Oct 27, 2025 | $80.00 |
| Oct 28, 2025 | $84.39 |
| Oct 29, 2025 | $92.19 |
| Oct 30, 2025 | $94.28 |
| Oct 31, 2025 | $94.15 |
| Nov 03, 2025 | $94.00 |
| 4 days before | 5.71% |
| 4 days after | 11.38% |
| On release day | 9.24% |
| Change in period | 17.75% |
| Release date | Feb 26, 2026 |
| Price on release | $91.69 |
| EPS estimate | $1.02 |
| EPS actual | $0.620 |
| EPS surprise | -39.22% |
| Date | Price |
|---|---|
| Feb 20, 2026 | $84.29 |
| Feb 23, 2026 | $82.08 |
| Feb 24, 2026 | $85.36 |
| Feb 25, 2026 | $94.31 |
| Feb 26, 2026 | $91.69 |
| Feb 27, 2026 | $92.95 |
| Mar 02, 2026 | $90.39 |
| Mar 03, 2026 | $91.40 |
| Mar 04, 2026 | $93.37 |
| 4 days before | 8.77% |
| 4 days after | 1.84% |
| On release day | 1.37% |
| Change in period | 10.77% |
| Release date | May 28, 2026 |
| Price on release | $82.81 |
| EPS estimate | $0.84 |
| EPS actual | $0.590 |
| EPS surprise | -29.76% |
| Date | Price |
|---|---|
| May 21, 2026 | $86.04 |
| May 22, 2026 | $86.01 |
| May 26, 2026 | $86.30 |
| May 27, 2026 | $82.95 |
| May 28, 2026 | $82.81 |
| May 29, 2026 | $86.77 |
| Jun 01, 2026 | $91.95 |
| Jun 02, 2026 | $89.28 |
| Jun 03, 2026 | $87.25 |
| 4 days before | -3.75% |
| 4 days after | 5.36% |
| On release day | 4.78% |
| Change in period | 1.41% |
Temenos AG Earnings Call Transcript Summary of Q1 2026
Temenos delivered a strong Q1 2026: product revenue and ARR grew above market (product revenue +14%, ARR +13%), maintenance showed robust premium upsell (maintenance +15%) and free cash flow improved (+22% Y/Y to $60m). The company reaffirmed 2026 guidance and 2028 targets while continuing an investment programme ($28–35m incremental investments, partly offset by ~$10m efficiencies). Operational leverage translated to non‑IFRS EBIT and EPS growth of ~20% and an improved EBIT margin (32.7%). Key strategic highlights: strong deal activity in Middle East & Africa and improving U.S. pipeline (several deals progressing), ongoing product roadmap acceleration with planned AI and composability launches in Q2, rollout of new pricing/packaging, and the appointment of Daniel Schmucki as CFO (joining Aug 3). Balance sheet and capital allocation: completed buybacks (CHF 100m in Apr; prior CHF 250m), net debt $609m, leverage 1.3x, and continued focus on R&D, selective bolt‑ons and progressive dividend policy. Management remains prudent on full‑year phasing despite the strong start, citing macro uncertainty and tougher comps in coming quarters.
